Gosset Ownership
Private
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Corline Biomedical General Information
Corline Biomedical has developed proprietary heparin-based coating technologies that are used commercially in medical devices to provide antithrombotic and anti-inflammatory properties. Its lead pharmaceutical candidate Renaparin® targets delayed graft function in kidney transplantation and related regenerative medicine applications. The company’s solutions have shown strong scientific support for improving patient outcomes by reducing thrombosis and immune responses associated with transplants and cell therapies. Clinical results are pending for the main drug pipeline; device coatings are already supplied commercially.
Contact Information
Primary Industry
Biotech
Corporate Office
Uppsala,
Sweden
Sweden
Drug Pipeline
CHS Coated Stent
CommercialKey Partnerships
Increased interest from partners in regenerative medicine sector
Corline Biomedical Funding
No funding data available
To view Corline Biomedical's complete valuation and funding history, request access »